摘要
目的:探讨索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床价值。方法:2012年5月-2014年5月收治Ⅲ型前列腺炎患者94例,将其平均分为观察组(n=47)和对照组(n=47),观察组采用索利那新联合坦索罗辛治疗,对照组采用林可霉素治疗,对两组治疗效果、不良反应发生率以及治疗后心理状态评分进行观察和统计。结果:观察组患者治愈率46.81%,明显高于对照组治愈率36.17%(P<0.05);观察组不良反应发生率4.26%,明显低于对照组不良反应发生率14.89%(P<0.05);观察组SAS及SDS评分明显低于对照组相关指标(P<0.05)。结论:索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床价值显著,有效改善了患者的临床症状,值得推广。
Objective:To explore the clinical value of solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis.Methods:94 cases with type Ⅲ prostatitis were selected from May 2012 to May 2014.They were divided into the observation group(n=47) and the control group(n=47).The observation group were treated with solifenacin combined with tamsulosin.The control group were treated with lincomycin.We compared the therapeutic effect,adverse reaction rate and mental status score after treatment of the two groups.Conclusion:In the observation group,the cure rate was 46.81%,which was significantly higher than the cure rate of 36.17% in the control group(P<0.05).In the observation group,the incidence of adverse reaction was 4.26%,which was significantly lower than that 14.89%of the control group(P<0.05).In the observation group,the SAS and the SDS score were significantly lower than those of the control group(P<0.05).Conclusion:Clinical value of solifenacin combined with tamsulosin in the treatment of type Ⅲ prostatitis is significant.It can effectively improve the clinical symptoms of patients,and it is worthy of promotion.
